Zevra Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
Zevra Therapeutics, Inc. (ZVRA) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 1.15 million shares for the 3-month period ending 2018-06-30, per its 10-Q filed 2019-08-13.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2019-08-13
- Zevra Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2018-06-30 was 1.15M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month |
|---|---|
| 2018-06-30 | 1.15M shares 10-Q · filed 2019-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |